Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 4/20 | 0.47 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3648802 | 0.91 | HTT (0.43) | METTNIKHTTPDE10AJAK2 | |
| SCHEMBL8060597 | 0.89 | GRM5 (0.45) | AXLSMN1; SMN2 | |
| SCHEMBL3655694 | 0.83 | MET (0.63) | METPDE10AJAK2 | |
| SCHEMBL13058517 | 0.80 | TNIK (0.54) | TNIKMAPK10MAPK9NPC1RAB9A | |
| SCHEMBL3653545 | 0.79 | SCN9A (0.47) | MAPK10DGAT1ABL1 | |
| SCHEMBL8055628 | 0.76 | EPHX2 (0.53) | METEGFR | |
| SCHEMBL3655673 | 0.75 | MET (0.54) | METJAK2JAK1TYK2JAK3 | |
| SCHEMBL3650603 | 0.74 | FYN (0.42) | TNIKHTTPIK3CAMTOR | |
| SCHEMBL8068266 | 0.73 | MET (0.49) | METTNIKJAK2MAPK10CSF1R | |
| SCHEMBL27818696 | 0.72 | CHEK1 (0.48) | TNIKMAPTPIK3CADGAT1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298325-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | SENEXIS LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| US-20100298325-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | SENEXIS LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| US-20100298325-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | SENEXIS LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| EP-2205317-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | Senexis Limited (GB) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009044160-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | SENEXIS LIMITED (GB) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298325-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | HCRTR1, HCRTR2, RTN3 | MET 463/4885TNIK 4832/4885HTT 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.